206 related articles for article (PubMed ID: 38191387)
1. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
de Jong VMT; Wang Y; Ter Hoeve ND; Opdam M; Stathonikos N; Jóźwiak K; Hauptmann M; Cornelissen S; Vreuls W; Rosenberg EH; Koop EA; Varga Z; van Deurzen CHM; Mooyaart AL; Córdoba A; Groen EJ; Bart J; Willems SM; Zolota V; Wesseling J; Sapino A; Chmielik E; Ryska A; Broeks A; Voogd AC; Loi S; Michiels S; Sonke GS; van der Wall E; Siesling S; van Diest PJ; Schmidt MK; Kok M; Dackus GMHE; Salgado R; Linn SC
J Clin Oncol; 2022 Jul; 40(21):2361-2374. PubMed ID: 35353548
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
Park JH; Jonas SF; Bataillon G; Criscitiello C; Salgado R; Loi S; Viale G; Lee HJ; Dieci MV; Kim SB; Vincent-Salomon A; Curigliano G; André F; Michiels S
Ann Oncol; 2019 Dec; 30(12):1941-1949. PubMed ID: 31566659
[TBL] [Abstract][Full Text] [Related]
4. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.
de Boo LW; Jóźwiak K; Ter Hoeve ND; van Diest PJ; Opdam M; Wang Y; Schmidt MK; de Jong V; Kleiterp S; Cornelissen S; Baars D; Koornstra RHT; Kerver ED; van Dalen T; Bins AD; Beeker A; van den Heiligenberg SM; de Jong PC; Bakker SD; Rietbroek RC; Konings IR; Blankenburgh R; Bijlsma RM; Imholz ALT; Stathonikos N; Vreuls W; Sanders J; Rosenberg EH; Koop EA; Varga Z; van Deurzen CHM; Mooyaart AL; Córdoba A; Groen E; Bart J; Willems SM; Zolota V; Wesseling J; Sapino A; Chmielik E; Ryska A; Broeks A; Voogd AC; van der Wall E; Siesling S; Salgado R; Dackus GMHE; Hauptmann M; Kok M; Linn SC
ESMO Open; 2024 Mar; 9(3):102923. PubMed ID: 38452438
[TBL] [Abstract][Full Text] [Related]
7. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
8. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF
J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.
Martín M; Yoder R; Salgado R; Del Monte-Millán M; Álvarez EL; Echavarría I; Staley JM; O'Dea AP; Nye LE; Stecklein SR; Bueno C; Jerez Y; Cebollero M; Bueno O; García Saenz JÁ; Moreno F; Bohn U; Gómez H; Massarrah T; Khan QJ; Godwin AK; López-Tarruella S; Sharma P
Clin Cancer Res; 2024 May; 30(10):2160-2169. PubMed ID: 38466643
[TBL] [Abstract][Full Text] [Related]
10. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Loi S; Drubay D; Adams S; Pruneri G; Francis PA; Lacroix-Triki M; Joensuu H; Dieci MV; Badve S; Demaria S; Gray R; Munzone E; Lemonnier J; Sotiriou C; Piccart MJ; Kellokumpu-Lehtinen PL; Vingiani A; Gray K; Andre F; Denkert C; Salgado R; Michiels S
J Clin Oncol; 2019 Mar; 37(7):559-569. PubMed ID: 30650045
[TBL] [Abstract][Full Text] [Related]
12. Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and
Telli ML; Chu C; Badve SS; Vinayak S; Silver DP; Isakoff SJ; Kaklamani V; Gradishar W; Stearns V; Connolly RM; Ford JM; Gruber JJ; Adams S; Garber J; Tung N; Neff C; Bernhisel R; Timms KM; Richardson AL
Clin Cancer Res; 2020 Jun; 26(11):2704-2710. PubMed ID: 31796517
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of
Sharma P; Stecklein SR; Kimler BF; Sethi G; Petroff BK; Phillips TA; Tawfik OW; Godwin AK; Jensen RA
J Cancer Ther Res; 2014 Mar; 3(2):1-11. PubMed ID: 25177489
[TBL] [Abstract][Full Text] [Related]
14. HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Baez-Navarro X; van den Ende NS; Nguyen AH; Sinke R; Westenend P; van Brakel JB; Stobbe C; Westerga J; van Deurzen CHM
Breast Cancer Res; 2024 Mar; 26(1):41. PubMed ID: 38468323
[TBL] [Abstract][Full Text] [Related]
15. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
17. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
18. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
19. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
